Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.
Clinical trial details
Phase I, first-in human, open-label, dose escalation and cohort expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and antitumour activity of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphoma
Identifier
LB-208-001
Sponsor
LEUKOS BIOTECH, S. L.
Principal Investigator
IRENE BRAÑA GARCIA
Service
Oncology
Cohort for hematological patients available
Study details
Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: I
Randomization: Non-randomized
Molecular details
Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: LB-208 (HTR1B antagonist)
Drug details
Arm A: LB-208 (HTR1B antagonist)
Links
Clinical Trials GOV (NCT identifier):
NL
EU Clinical Trials Register (eudraCT Identifier):
Not applicable
